$-12.16
(Market cap
$53,061 Mln
Recently Viewed
Clear AllMarket cap
$53,061 Mln
Revenue (TTM)
$4,164 Mln
P/E Ratio
43.3
P/B Ratio
7.2
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$1,296 Mln
ROE
0.2 %
ROCE
20 %
Industry P/E
--
EV/EBITDA
36.8
Debt to Equity
0
Book Value
$110.6
EPS
$19.6
Face value
--
Shares outstanding
62,187,771
CFO
$-2,281.02 Mln
EBITDA
$-2,075.38 Mln
Net Profit
$-2,407.69 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
argenx SE - ADR
| -5.7 | 19.5 | -2.8 | 33.2 | 26.8 | 22.3 | -- |
|
BSE Sensex*
| -8.3 | 4.2 | -5.6 | -2.4 | 9.2 | 10.1 | 11.6 |
|
S&P 100#
| 1.3 | 10.0 | 2.4 | 37.5 | 22.9 | 13.3 | 14.2 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
argenx SE - ADR
| 36.7 | 61.3 | 0.2 | 8.2 | 19.1 | 83.2 | 67.1 |
|
S&P 100
| 18.7 | 29.0 | 30.8 | -22.1 | 27.6 | 19.3 | 29.5 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
argenx SE - ADR
|
793.2 | 53,060.7 | 4,164.2 | 1,296.0 | 9.5 | 20.2 | 43.3 | 7.2 |
| 4.0 | 455.5 | 73.2 | -67.8 | -82.1 | -65.5 | -- | 5.9 | |
| 19.6 | 1,263.0 | 0.0 | -147.4 | -29,734.7 | -150.3 | -- | 7.5 | |
| 29.1 | 1,966.4 | 1,112.2 | 320.9 | -17.8 | 10.5 | 5.1 | 0.5 | |
| 27.7 | 17,527.2 | 3,722.9 | 963.8 | 40.1 | 4.5 | 18.5 | 3.0 | |
| 14.6 | 2,706.5 | 550.0 | 458.1 | -3.3 | 45.9 | 5.9 | 2.2 | |
| 17.1 | 1,224.6 | 403.3 | 22.8 | 3,081.6 | 9.1 | 433.5 | 4.4 | |
| 4.0 | 687.9 | 4.6 | -201.1 | -4,342.4 | -146.8 | -- | 5.7 | |
| 5.3 | 535.3 | 174.7 | -115.2 | 0.0 | -80.2 | -- | 4.1 | |
| 22.9 | 2,732.0 | 460.2 | -175.5 | -37.7 | -22.6 | -- | 3.8 |
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and... immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands. Read more
CEO & Executive Director
Mr. Timothy Van Hauwermeiren EMBA, M.B.A., M.Sc.
CEO & Executive Director
Mr. Timothy Van Hauwermeiren EMBA, M.Sc.
Headquarters
Amsterdam
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of argenx SE - ADR is $793.22 (NASDAQ) as of 22-Apr-2026 16:00 EDT. argenx SE - ADR has given a return of 26.77% in the last 3 years.
The P/E ratio of argenx SE - ADR is 43.30 times as on 17-Apr-2026.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
42.95
|
7.60
|
|
2024
|
52.38
|
7.94
|
|
2023
|
-75.01
|
5.40
|
|
2022
|
-29.53
|
7.45
|
|
2021
|
-44.25
|
7.12
|
The 52-week high and low of argenx SE - ADR are Rs 934.62 and Rs 510.06 as of 23-Apr-2026.
argenx SE - ADR has a market capitalisation of $ 53,061 Mln as on 17-Apr-2026. As per SEBI classification, it is a Large Cap company.
Before investing in argenx SE - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.